Changes in Hong Kong stocks | Some innovative drug concept stocks are rising, the National Health Insurance Administration says that more innovative drugs are expected to be included in health insurance reimbursement, and health insurance talks will soon be held

Zhitong Finance App learned that some innovative drug concept stocks were higher. As of press release, Kangfang Biotech (09926) rose 11.67% to HK$101.4; Nuocheng Jianhua (09969) rose 4.6% to HK$15.45; Hehuang Pharmaceutical (00013) rose 3.11% to HK$22.56; and BeiGene Shenzhou (06160) rose 1.92% to HK$222.4.

According to the news, Li Tao, deputy director of the National Health Insurance Administration, said at a press conference on the “Getting Started” series held by the State Information Office on September 4 that he will continue to adjust the basic medical insurance drug catalogue every year, include more eligible innovative drugs for major diseases and key areas such as tumors, chronic diseases, rare diseases, and childhood diseases in medical insurance reimbursement, and focus on promoting the national unification of medical service programs and medical consumables reimbursement catalogues to further reduce policy differences between regions.

It is worth noting that, according to the Securities Times, the 2026 national basic medical insurance drug catalogue negotiation and commercial insurance innovative drug catalogue price negotiation work will begin on September 5 at the National People's Congress Center. Preliminary communication between the National Health Insurance Administration and the negotiating companies was completed last week. Price negotiations on the commercial insurance innovative drug catalogue will also be carried out simultaneously this year, and a new edition of the commercial insurance innovative drug catalogue will be drawn up.